Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + etoposide + prednisone + cyclophosphamide + doxorubicin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b, a component of the B-cell receptor. It is composed of a humanized IgG1 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). In the context of the Phase 2 study led by Weill Medical College of Cornell University, polatuzumab vedotin is combined with a modified R-EPOCH chemoimmunotherapy regimen—consisting of rituximab, etoposide, prednisone, cyclophosphamide, and doxorubicin (hydroxydaunomycin)—for the treatment of Richter's Transformation. Richter's Transformation is an aggressive progression of chronic lymphocytic leukemia (CLL) into diffuse large B-cell lymphoma (DLBCL). This combination aims to improve outcomes in this high-risk population by adding a targeted ADC to a backbone of intensive infusional chemotherapy.
- Brand names
- PolivyRituxan
- Other names
- Polatuzumab vedotin + R-EPOCHPola-R-EPOCHPolatuzumab vedotin + R-CHOPPolatuzumab vedotin + R-EPCH
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)B-cell antigen receptor complex-associated protein beta chainGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + etoposide + prednisone + cyclophosphamide + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + etoposide + prednisone + cyclophosphamide + doxorubicin.